Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis

Journal of the American Academy of Dermatology

Volumn 62, Issue 1, 2010, Pages 142-144

  Hamaguchi, Yasuhito ^a   Fujimoto, Manabu ^a   Hasegawa, Minoru ^a   Matsushita, Takashi ^a   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CONSULTATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; LUNG FUNCTION TEST; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ADULT; DNA TOPOISOMERASES, TYPE I; FEMALE; GLUCOCORTICOIDS; HUMANS; PREDNISOLONE; SCLERODERMA, DIFFUSE; SKIN;

EID: 71649108327     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.01.032     Document Type: Article

References (13)

1. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44 (1989) 93-151
2. Kuwana M., Kaburaki J., Okano Y., Tojo T., and Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37 (1994) 75-83
3. Hamaguchi Y., Hasegawa M., Fujimoto M., Matsushita T., Komura K., Kaji K., et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158 (2008) 487-495
4. Shero J.H., Bordwell B., Rothfield N.F., and Earnshaw W.C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231 (1986) 737-740
5. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35 (2005) 35-42
6. Steen V.D., and Medsger Jr. T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41 (1998) 1613-1619
7. Steen V.D., and Medsger Jr. T.A. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 16 (1990) 1-10
8. Reveille J.D., and Solomon D.H. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49 (2003) 399-412
9. Vázquez-Abad D., Russell C.A., Cusick S.M., Earnshaw W.C., and Rothfield N.F. Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 74 (1995) 257-270
10. Hu P.Q., Fertig N., Medsger Jr. T.A., and Wright T.M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48 (2003) 1363-1373
11. Sato S., Hamaguchi Y., Hasegawa M., and Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 40 (2001) 1135-1140
12. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., and Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43 (2000) 1074-1084
13. Hénault J., Robitaille G., Senécal J.L., and Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54 (2006) 963-973